Compound Detail
CHEMBL1201746
PRALATREXATE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
C#CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1
Basic Information
| ChEMBL ID | CHEMBL1201746 |
| Name | PRALATREXATE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | OGSBUKJUDHAQEA-WMCAAGNKSA-N |
| Therapeutic | ✓ Yes |
11
Targets
17
Activities
3
Assay Types
0
PK Parameters
20
Publications
5
Known Names
19
Indications
1
Mechanisms
Molecular Properties
477.5
MW (Da)
0.98
ALogP
9
HBA
5
HBD
207.3
PSA (Ų)
0.26
QED
0
Ro5 Violations
10
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2009 |
| Availability | Prescription |
| Chirality | Racemic |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Dihydrofolate reductase inhibitor | INHIBITOR | Dihydrofolate reductase | ✓ | ✓ |
Indications
Lymphoma, T-Cell Lymphoma, T-Cell, Peripheral Lymphoma, T-Cell, Peripheral Neoplasms Neoplasms Lymphoma Breast Neoplasms Carcinoma, Non-Small-Cell Lung Head and Neck Neoplasms Leukemia-Lymphoma, Adult T-Cell Lung Neoplasms Fallopian Tube Neoplasms Lymphoma, Large-Cell, Anaplastic Lymphoma, T-Cell, Cutaneous Multiple Myeloma Mycosis Fungoides Ovarian Neoplasms Peritoneal Neoplasms Sezary Syndrome
ATC Classification
L01BA05
pralatrexate
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: ANTINEOPLASTIC AGENTS
Activity Summary
IC50 14 meas. best 9.33
Ki 2 meas. best 10.87
EC50 1 meas. best 8.1
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Bifunctional dihydrofolate reductase-thymidylate synthase CHEMBL1939 | Ki | 10.87 | 10.87 | 0.0 | 1 |
| Dihydrofolate reductase CHEMBL202 | Ki | 10.87 | 10.87 | 0.0 | 1 |
| KB CHEMBL398 | IC50 | 9.33 | 9.02 | 0.5 | 4 |
| NON-PROTEIN TARGET CHEMBL3879801 | IC50 | 9.16 | 7.97 | 0.7 | 2 |
| Reduced folate transporter CHEMBL4833 | IC50 | 9.16 | 9.16 | 0.7 | 1 |
| SARS-CoV-2 CHEMBL4303835 | EC50 | 8.1 | 8.1 | 8.0 | 1 |
| Proton-coupled folate transporter CHEMBL1795188 | IC50 | 7.24 | 7.24 | 57.0 | 1 |
| R2 CHEMBL614385 | IC50 | 7.24 | 7.24 | 57.0 | 1 |
| SARS-CoV-2 CHEMBL4303835 | IC50 | 7.22 | 7.22 | 60.0 | 2 |
| Folate receptor alpha CHEMBL2121 | IC50 | 6.78 | 6.78 | 168.0 | 1 |
| Unchecked CHEMBL612545 | IC50 | 6.09 | 6.09 | 819.0 | 1 |
| ADMET CHEMBL612558 | IC50 | 6.09 | 6.09 | 819.0 | 1 |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 6 |
| 24111942 | 10.1021/jm401139z | NON-PROTEIN TARGET | 5 |
| 24111942 | 10.1021/jm401139z | ADMET | 2 |
| - | 10.6019/CHEMBL4808148 | Histone deacetylase 6 | 2 |
| - | 10.6019/CHEMBL4495565 | ADMET | 2 |
| - | 10.6019/CHEMBL4495565 | Vero C1008 | 2 |
| - | 10.6019/CHEMBL4495564 | Replicase polyprotein 1ab | 2 |
| 29425443 | 10.1021/acs.jmedchem.7b01708 | KB | 2 |
| 29425443 | 10.1021/acs.jmedchem.7b01708 | Folate receptor beta | 2 |
| 29425443 | 10.1021/acs.jmedchem.7b01708 | Folate receptor alpha | 2 |
| 29425443 | 10.1021/acs.jmedchem.7b01708 | Unchecked | 2 |
| 26948801 | 10.1016/j.drudis.2016.02.015 | Homo sapiens | 2 |
| 24111942 | 10.1021/jm401139z | KB | 2 |
| 29425443 | 10.1021/acs.jmedchem.7b01708 | Proton-coupled folate transporter | 1 |
| - | 10.21203/rs.3.rs-23951/v1 | SARS-CoV-2 | 1 |
| - | 10.1101/2020.04.21.054387 | SARS-CoV-2 | 1 |
| 29425443 | 10.1021/acs.jmedchem.7b01708 | Reduced folate transporter | 1 |
| 24111942 | 10.1021/jm401139z | R2 | 1 |
| 33540357 | 10.1016/j.ejmech.2021.113218 | Dihydrofolate reductase | 1 |
| - | 10.6019/EOS300033 | SARS-CoV-2 | 1 |
Data from ChEMBL 36 via Core Engine